This company develops biosimilar therapeutics, focusing on creating affordable, high-quality versions of complex biologic medicines. Their work aims to expand patient access to essential treatments for various diseases.
Funding
Funding not disclosed
Founders
Product
Problem
The high cost of biologic medicines limits patient access to critical treatments for diseases like cancer, anemia, and autoimmune disorders. Expiring patents on biologics create an opportunity to offer more affordable alternatives.
Solution
Biosimilar Solutions develops and commercializes biosimilar therapeutics, providing cost-effective alternatives to expensive biologic drugs. Their biosimilars are designed to meet the same FDA standards for safety and efficacy as the reference biologics, ensuring patients receive high-quality care at a lower cost. By expanding access to these essential medicines, Biosimilar Solutions aims to alleviate the financial burden on patients and the healthcare system. The company's pipeline focuses on oncology supportive care biosimilars, with a strategic approach to product development and regulatory approval.
Target Audience
The primary target audience includes patients requiring biologic treatments, healthcare providers seeking cost-effective alternatives, and payers aiming to reduce healthcare expenditures.
Features
- Biosimilars with highly similar structure and function to reference biologics
- Adherence to FDA and EMA regulatory guidelines
- Focus on oncology supportive care biosimilars
- Defined regulatory pathway and known clinical design
- Evidence of patient safety